1. Ipsilateral and contralateral coadministration of influenza and COVID-19 vaccines produce similar antibody responses.
- Author
-
Pattinson D, Jester P, Gu C, Guan L, Armbrust T, Petrie JG, King JP, Nguyen HQ, Belongia EA, Halfmann P, Neumann G, and Kawaoka Y
- Subjects
- Humans, Male, Female, Middle Aged, Adult, Antibody Formation immunology, Vaccination methods, Aged, Prospective Studies, Antibodies, Neutralizing blood, Antibodies, Neutralizing immunology, Influenza Vaccines immunology, Influenza Vaccines administration & dosage, Antibodies, Viral blood, Antibodies, Viral immunology, COVID-19 Vaccines immunology, COVID-19 Vaccines administration & dosage, COVID-19 prevention & control, COVID-19 immunology, SARS-CoV-2 immunology, Influenza, Human prevention & control, Influenza, Human immunology
- Abstract
Background: World Health Organisation (WHO) and USA Centers for Disease Control and Prevention (U.S. CDC) recommendations now allow simultaneous administration of COVID-19 and other vaccines. We compared antibody responses after coadministration of influenza and bivalent COVID-19 vaccines in the same (ipsilateral) arm vs. different (contralateral) arms., Methods: Pre- and post-vaccination serum samples from individuals in the Prospective Assessment of COVID-19 in a Community (PACC) cohort were used to conduct haemaglutination inhibition (HI) assays with the viruses in the 2022-2023 seasonal influenza vaccine and focus reduction neutralisation tests (FRNT) using a BA.5 SARS-CoV-2 virus. The effect of ipsilateral vs. contralateral vaccination on immune responses was inferred in a model that accounted for higher variance in vaccine responses at lower pre-vaccination titers., Findings: Ipsilateral vaccination did not cause higher influenza vaccine responses compared to contralateral vaccination. The response to SARS-CoV-2 was slightly increased in the ipsilateral group, but equivalence was not excluded., Interpretation: Coadministration of influenza and bivalent COVID-19 vaccines in the same arm or different arms did not strongly influence the antibody response to either vaccine., Funding: This work was supported by the U.S. CDC (grant number: 75D30120C09259)., Competing Interests: Declaration of interests Y.K. has received grant support from Daiichi Sankyo Pharmaceutical, Toyama Chemical, Tauns Laboratories, Shionogi, Otsuka Pharmaceutical, KM Biologics, Kyoritsu Seiyaku, Shinya Corporation, and Fuji Rebio. Y.K. and G.N. are co-founders of FluGen. H.Q.N receives research support unrelated to this work from CSL Seqirus and GSK and honorarium for participating in a consultancy group for Moderna outside the submitted work. J.G.P. and E.A.B. receive research support unrelated to this work from CSL Seqirus. J.P.K. receives research support unrelated to this work from GSK., (Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF